Witness For Justice #862 - It is up to us to stop gun violence

Witness For Justice #862 - It is up…

Truly God is good to the ...

“What a Tragedy It Would Be…!”

“What a Tragedy It Would Be…!”

To have gone through your...

Jemele Hill Suspended after Tweets About Cowboys Owner

Jemele Hill Suspended after Tweets …

ESPN has suspended one of...

Medicare Open Enrollment Season Is Here

Medicare Open Enrollment Season Is …

When you shop for a new c...

My Story: Founder of Sisters Network Shares “It Takes More Than A Mammogram” To Fight Breast Cancer

My Story: Founder of Sisters Networ…

Most women believe that i...

Prev Next

SB News Header Image

P.O. Box 837, Victorville, CA 92393            Office: (909) 889-7677            E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.           Web:
A+ A A-

More than 50 Dead, 400 Injured in Las Vegas Mass Shooting

Was this an act of terrorism, what do you think? Follow us on Twitter

Las Vegas authorities have identified Stephen Paddock, a 64 year-old White man from Mesquite, Nevada, as the gunmen in one of the deadliest mass shootings in United States history.

During a brief press conference Monday morning, Clark County Sheriff Joseph Lombardo told reporters that more than 50 people were killed and more than 400 people that were wounded during the attack were transported to local hospitals following the attack, according to the New York Times. Police have determined that Paddock fired on the crowd of roughly 22,000 attending a country music festival from his room on the 32nd floor of the Mandalay Bay Resort and Casino Sunday night.

“Online video of the attack outside the Mandalay Bay Resort and Casino showed the singer Jason Aldean performing outside at the Route 91 Harvest Festival, a three-day country music event, interrupted by the sound of automatic gunfire,” The New York Times reported. “The music stopped, and concertgoers ducked for cover.”

Authorities haven’t reported anything about Paddock’s motive; not much is known about the weapons used in the attack, although some experts have speculated that multiple firearms were used, including a high-caliber, automatic rifle.

Police have reported that Paddock died from a self-inflicted gunshot wound.

According to NBC News, “The brother of Las Vegas gunman Stephen Paddock was stunned to learn Monday that his relative was the suspected perpetrator of the largest mass shooting in modern American history. Paddock, who lives in Orlando, said his brother has retired to Mesquite, Nevada and spent his time at the hotels, going to shows and gambling.”

During an interview with NBC News, Paddock said that his brother, “was just a guy” and that the family was “completely at a loss.”

Monday morning, President Donald Trump tweeted, “My warmest condolences and sympathies to the victims and families of the terrible Las Vegas shooting. God bless you!”

Lin-Manuel Miranda, the American composer and playwright of the award-winning play “Hamilton,” also took to Twitter to share condolences for people affected by the tragedy in Las Vegas.

“Heartbroken by the news out of Las Vegas,” Miranda said. “Praying for those of us waiting for news from loved ones who went to hear live music on a Sunday.”

During an interview with MSNBC, Danny Tarkanian, a Republican candidate for the U.S. Senate from Nevada said that the attack was “the worst fear of anybody who has lived in Las Vegas.”

Jamelle Bouie, the chief political correspondent for, questioned why authorities hesitated to call the mass shooting an act of terrorism.

“That Las Vegas authorities have ruled out terrorism at this early stage is another example of how the idea has all but been racialized,” Bouie tweeted.

Writer and social media activist Shaun King suggested that the shooter’s “whiteness” prevented authorities from calling him a terrorist, even though he “conducted the deadliest mass shooting in American history.

As some took to social media calling for the mass shooting to be labeled an act of terrorism, others used the tragedy to call for stricter gun control.

Still, most social media users continued to share sympathy and prayers for the concertgoers and their families.

“Don’t even know what to say,” R&B singer Trey Songz tweeted. “To be in Vegas while this is happening, brings a pain to my heart. My team and I are safe Thank God! Prayers up.”

NBA superstar Isaiah Thomas tweeted, “Prayers up for the victims & families of the Las Vegas Shooting! #PrayForVegas”

Dr. Benjamin F. Chavis, Jr., the president and CEO of the National Newspaper Publishers Association offered prayers and sympathy, while calling for a deeper conversation about the role that guns play in American society.

“NNPA affirms heartfelt condolences to families impacted by senseless murders in Las Vegas,” said Chavis on Twitter. “End gun violence!”


NNPA, Pfizer Release Groundbreaking Poll about Sickle Disease in the Black Community

NNPA President and CEO Benjamin F. Chavis, Jr. (far left) and NNPA Chairman Dorothy Leavell (3rd from left) joined researchers from Howard University and Pfizer officials to release a new poll on sickle cell disease at the National Press Club in Washington, D.C. (Freddie Allen/AMG/NNPA)

A new poll about sickle cell disease (SCD), presented by the National Newspaper Publishers Association (NNPA) and Pfizer revealed that while the majority of respondents were familiar with the illness, less than 40 percent realized that it disproportionately affects people of African descent.

The NNPA is a trade group that represents more than 200 African American-owned community newspapers operating in the United States. Earlier this year, Pfizer partnered with the NNPA to increase awareness about SCD in the Black community and to encourage greater participation in clinical trials for treatments involving the disease.

The groundbreaking poll also helped to dispel one of the long-held myths about the negative perception of medical professionals in the Black community.

The poll revealed that, despite long-standing historical perceptions of mistrust in medical professionals by the Black community, 91 percent of respondents indicated that they believe health care professionals are trustworthy.

Seventy-nine percent of respondents had positive or neutral attitudes toward sickle cell disease (SCD) trials and a majority indicated a willingness to participate in future clinical trials for SCD, given appropriate knowledge and recommendations from health care professionals.

“Our core belief is that every patient counts, especially when it comes to rare disease,” said Michael Goettler, the global president of Pfizer’s Rare Disease unit. “When you have a rare disease, often you feel lonely and your physician may not be able to help you.”

Goettler noted that the poll results provide a basis for Pfizer to seek more detailed assistance for sufferers.

Even though the greatest burden for SCD, the report said that there’s limited research regarding African-Americans’ knowledge and thoughts about clinical trials that study the health impacts of the illness, the report said.

“These poll findings will give our readers an in-depth understanding of how sickle cell disease is perceived by African-Americans,” said Dr. Benjamin F. Chavis, Jr., president and CEO of the NNPA. “With this knowledge from the dedicated research team at Howard University, and through our collaboration with Pfizer, we can spur meaningful conversation and assess the best ways to improve disease education for those impacted in our communities.”

Dorothy Leavell, the chairman of the NNPA, said that she’s pleased to be a part of a group delivering “good news,” as well as the research that Pfizer continues to embark upon, on behalf of SCD patients.

SCD is a lifelong and debilitating disorder that affects red blood cells and it’s the most common inherited blood disorder in the U.S. Most people who live with SCD are of African descent and the disease occurs in one out of 365 African-American births.

The median age of death for sickle cell disease patients in America hovers in the mid-40s, said Dr. Kevin Williams, the chief medical officer for Pfizer’s Rare Disease unit. Williams also writes a regular column about SCD for NNPA, titled “Ask Dr. Kevin.”

Williams said that the insight form the poll will not only help researchers determine how to further enhance disease education and awareness, but will also help Pfizer educate SCD patients and their families about the importance of clinical trials in bringing novel treatment options to market for those in need.

The survey was conducted by researchers at Howard University, who made 31,934 telephone calls for the poll that was conducted between June 15 and July 15. A total of 741 individuals aged 20 to 70 living across the country, who identified as being of African-American ethnicity, responded to the survey.

The majority of respondents (79 percent) said they understood the importance of disease education and expressed the need for additional current information, specifically regarding pain relief, clinical trials and progress toward better treatment or a cure.

“It’s not surprising for us that a majority of our participants understood and were previously aware of sickle cell disease,” said Dr. Terri Adams, an associate dean in the College of Arts and Sciences at Howard University. “The overwhelming majority understood that it’s a disease, a blood disorder.”

Adams continued: “There was a willingness to participate in [SCD] clinical trials, however, 82 percent had very or somewhat negative attitudes toward clinical trials in general, so there’s still a general mistrust in clinical trials.”

Researchers and officials at Pfizer and the NNPA each said that they hope to continue to educate patients, family members and primary care doctors about SCD clinical trials.

“Close to 20 percent said they were unsure of how it was inherited and this presents a problem,” Adams said. “If you don’t know how it’s inherited, you may be putting your offspring at risk.”


Pfizer And The National Newspaper Publishers Association Collaborate To Raise Awareness Of Sickle Cell Disease And Need For Improved Patient Care

NEW YORK, NY, March 24, 2017 – Pfizer Inc. (NYSE:PFE) and the National Newspaper Publishers Association (NNPA), a trade association of more than 200 African-American–owned community newspapers from around the United States, are collaborating to raise awareness of sickle cell disease, a lifelong and debilitating genetic disorder that affects red blood cells.

People with rare diseases, like sickle cell disease, have unique and complex challenges. The first initiative under the collaboration will be a national poll, conducted in partnership with Howard University’s Interdisciplinary Research Team in Washington, DC. The goal is to assess the awareness of sickle cell disease, the challenges of living with the disease, and the importance of clinical trial participation in helping researchers succeed in developing potential new treatments. In a review of 174 sickle cell disease trials, difficulty enrolling patients was the stated cause in nearly half of the 30% of the trials that were terminated early.

“This collaboration with Pfizer provides an opportunity for NNPA to inform and educate the readers of our 211-member Black-owned newspapers in more than 70 markets across the country on sickle cell disease, an often misunderstood disease that has a profound impact on the health and well-being of those affected,” said Dr. Benjamin F. Chavis, Jr., NNPA President. “Together with Pfizer, we look forward to providing sickle cell disease education that can underscore the importance of improving quality of care in the community.”

Sickle cell disease is the most common inherited blood disorder in the United States, affecting nearly 100,000 Americans. Although it affects many different ethnic groups, the majority of people with sickle cell disease are of African descent. In the United States, sickle cell disease occurs in approximately 1 out of every 365 African-American births. Access to care and delivery of innovative treatments prove to be among the most significant challenges faced by people living with sickle cell disease in America.

“At Pfizer, we are committed to delivering life-changing therapies to people living with rare diseases, like sickle cell disease,” said Kevin Williams, Chief Medical Officer for Pfizer’s Rare Disease unit. “Our commitment also goes beyond clinical research to supporting the rare disease community through innovative collaborations. Working together, we hope to improve awareness and ultimately address the unmet medical needs of sickle cell disease patients.”

The poll results and information about sickle cell disease will be shared with the NNPA network and incorporated into educational programs at NNPA events. More information about sickle cell disease can be found at For more information about the NNPA, please visit

[1] Lebensburger JD, Pair L, Hilliard L, et al. Systematic review of interventional sickle cell trials registered in Clin Trials. 2015:12(6);575-583.

[2] Sickle Cell Disease Research & Care. National Heart, Lung, and Blood Institute. US National Institutes of Health. Accessed May 26, 2016.

[3] Sickle Cell Anemia. American Society of Hematology. Accessed May 26, 2016.

[4] Data & Statistics. Centers for Disease Control and Prevention. Accessed January 25, 2017.

Subscribe to this RSS feed


About Us

Follow Us